Upadacitinib Medicine 03 June 2025 Extended indication Non-segmental Vitiligo in adolescents, adults and elderly who are eligible for systemic therapy. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Upadacitinib Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Skin diseases Extended indication Non-segmental Vitiligo in adolescents, adults and elderly who are eligible for systemic therapy. Current proprietary name Already available biosimilars / generics Proprietary name Rinvoq Manufacturer Abbvie Portfolio holder Abbvie Mechanism of action JAK tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date 2026 Expected Registration 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van informatie fabrikant. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation De fase 2 studie is gepubliceerd. De doses die in de studie werden gebruikt komen niet overeen met de huidige upadacitinib dosis op de markt. Er loopt op dit moment nog een fase 3 studie. Duration of treatment Frequency of administration Dosage per administration References NCT06118411 (Viti-Up) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Volksgezondheidenzorg.info Additional remarks Bij 0,5 tot 1% van de bevolking ontstaat vitiligo, ongeacht geslacht of afkomst. Dit zijn dus 85.000 tot 170.000 mensen in Nederland. Het is op dit moment nog niet in te schatten hoeveel patiënten er in aanmerking komen voor een orale JAK-remmer. Expected cost per patient per year Cost € < 9,700.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks Een tablet Rinvoq 15mg kost €28,94 (inclusief BTW) (1). Een jaarbehandeling zou €9.697,29 (exclusief BTW) per patiënt per jaar kosten (€28,94/1,09*365,24). Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks